Febuxostat is a second-line option for patients with gout who are unable to take allopurinol ... Febuxostat is not recommended for the treatment of patients with secondary hyperuricemia, such ...

The current target of gout treatment is to reduce levels down to 6 mg/dL or less. SEL-212 is based on a uricase enzyme (pegadricase) that breaks down uric acid in the blood combined with an immune ...

Researchers from the University of the Philippines Manila have developed a gout medication made of ulasimang bato, also known as pansit-pansitan. The drug, which comes in tablet form, has been shown ...

Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...